Skip to main content

Prostate cancer: profiling and evaluation of ncRNA

Cel

Annually, over 200 000 new prostate cancer cases are diagnosed in Europe. This number is expected to further increase due to widespread use of prostate specific antigen (PSA) tests on asymptomatic men and an aging population. This leads to high rate of over-detection, where most cases will never experience cancer symptoms during their lifetime. Hence, our current lack of means to predict prostate cancer prognosis will have devastating impact on both life-quality and health care expenditures. Molecular mechanisms of the development of prostate cancer are largely unknown apart from the recognized role of androgens. Lack of knowledge on mechanisms leading to the development and progression of this cancer hampers development of efficacious prevention, specific diagnostics, prognostic, and therapeutic tools. Based on the emerging knowledge on the function of non-coding RNAs (ncRNAs) as regulators of key cellular mechanisms and our own preliminary data on expression of ncRNAs in prostate cancer, it is very likely that ncRNAs are involved in the tumorigenesis and progression of prostate cancer. Our planned studies of ncRNAs can contribute major breakthroughs to optimize individualized prostate cancer treatment by providing both novel biomarkers and drug targets. In this project, we will pursue two major clinical problems: 1) early identification of cases requiring aggressive curative treatment, and 2) develop efficient therapies against hormone-refractory prostate cancer. The project will cover all phases of translational research, from discovery to validation and implementation. We will identify novel ncRNAs, investigate their expression, genetic/epigenetic alterations, and function. We will develop diagnostic tools, identify and validate therapeutic targets. To assure the success of the project, our consortium consists of leading translational prostate cancer research centers in Europe and companies committed to develop ncRNA detection technologies and novel drugs.

Zaproszenie do składania wniosków

FP7-HEALTH-2007-A
Zobacz inne projekty w ramach tego zaproszenia

Koordynator

TAMPEREEN YLIOPISTO
Adres
Kalevantie 4
33014 Tampere
Finlandia

Zobacz na mapie

Rodzaj działalności
Higher or Secondary Education Establishments
Kontakt administracyjny
Hannele Auffermann (Ms.)
Wkład UE
€ 639 568

Uczestnicy (7)

ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
Niderlandy
Wkład UE
€ 452 520
Adres
Dr Molewaterplein 40
3015 GD Rotterdam

Zobacz na mapie

Rodzaj działalności
Higher or Secondary Education Establishments
Kontakt administracyjny
Nuran Tuzen (Ms.)
THE UNIVERSITY OF SHEFFIELD
United Kingdom
Wkład UE
€ 371 296
Adres
Firth Court Western Bank
S10 2TN Sheffield

Zobacz na mapie

Rodzaj działalności
Higher or Secondary Education Establishments
Kontakt administracyjny
Joanne Watson (Ms.)
LUNDS UNIVERSITET
Szwecja
Wkład UE
€ 448 680
Adres
Paradisgatan 5c
22100 Lund

Zobacz na mapie

Rodzaj działalności
Higher or Secondary Education Establishments
Kontakt administracyjny
Kristian Riesbeck (Prof.)
EXIQON AS
Dania
Wkład UE
€ 449 400
Adres
Bygstubben 9
2950 Vedbaek

Zobacz na mapie

Rodzaj działalności
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Kontakt administracyjny
Søren Echwald (Dr.)
ORION OYJ
Finlandia
Wkład UE
€ 93 000
Adres
Orionintie 1
02200 Espoo

Zobacz na mapie

Rodzaj działalności
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Kontakt administracyjny
Ville Hassinen (Mr.)
TURUN YLIOPISTO
Finlandia
Wkład UE
€ 451 752
Adres
Yliopistonmaki
20014 Turku

Zobacz na mapie

Rodzaj działalności
Higher or Secondary Education Establishments
Kontakt administracyjny
Eliisa Särkilahti (Dr.)
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
United Kingdom
Wkład UE
€ 80 000
Adres
Wellington Square University Offices
OX1 2JD Oxford

Zobacz na mapie

Rodzaj działalności
Higher or Secondary Education Establishments
Kontakt administracyjny
Linda Polik (Ms.)